UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: August 2025
Commission File Number: 001-38428
PolyPid Ltd.
(Translation of registrant’s name into
English)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form
40-F
CONTENTS
Attached hereto and incorporated herein is PolyPid
Ltd.’s (the “Registrant”) press release issued on August 12, 2025, titled “PolyPid Appoints Dr. Nurit Tweezer-Zaks
as Chief Medical Officer.”
The
first and the third paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by
reference into the Company’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658,
File No. 333-281863, File No. 333-284376 and File No. 333-289034) and
Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703 and File No. 333-280662)
filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release issued by PolyPid Ltd. on August 12, 2025, titled “PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer.” |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
POLYPID LTD. |
| |
|
|
| Date: August 12, 2025 |
By: |
/s/ Dikla Czaczkes Akselbrad |
| |
|
Name |
: Dikla Czaczkes Akselbrad |
| |
|
Title: |
Chief Executive Officer |
3
